Benzinga

Benzinga

Benzinga

sábado, agosto 22

Perspective Therapeutics Inc

CATXAMEX
Trade with Public
Trade with Public
$3.30
0.092.8%
al cierre: Aug 21, 5:00 PM EST
Panorámica generalNoticiasPrevisión de beneficiosEventosPrecios objetivoFinanzasSentimientoPropiedadCompararInforme de acciones

Perspective Therapeutics Analyst Price Targets

Wall Street analyst price targets and consensus rating for Perspective Therapeutics (CATX).

Price Target Range — 12 Quarters

Analyst Consensus — 14 Analysts

13Buy
1Hold
Consensus RatingBuy# Analysts14Avg. Consensus PT$11

Rating Trend — Last 9 Months

Recent Analyst Actions

View all ratings →
DateFirmAnalystActionRating ChangePrice Target
Aug 19, 2026BMO CapitalDavid LebowitzInitiateOutperform$11
Aug 14, 2026B of A SecuritiesAlec StranahanPT CutNeutral$6→$5
More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
BMO Capital Initiates Coverage On Perspective Therapeutics with Outperform Rating, Announces Price Target of $11

BMO Capital analyst David Lebowitz initiates coverage on Perspective Therapeutics (AMEX:CATX) with a Outperform rating and announces Price Target of $11.
Benzinga Newsdesk

PRO
B of A Securities Maintains Neutral on Perspective Therapeutics, Lowers Price Target to $5

B of A Securities analyst Alec Stranahan maintains Perspective Therapeutics (AMEX:CATX) with a Neutral and lowers the price target from $6 to $5.
Benzinga Newsdesk

PRO
Piper Sandler Maintains Overweight on Perspective Therapeutics, Lowers Price Target to $14

Piper Sandler analyst Biren Amin maintains Perspective Therapeutics (AMEX:CATX) with a Overweight and lowers the price target from $16 to $14.
Benzinga Newsdesk

PRO
Wedbush Reiterates Outperform on Perspective Therapeutics, Maintains $11 Price Target

Wedbush analyst David Nierengarten reiterates Perspective Therapeutics (AMEX:CATX) with a Outperform and maintains $11 price target.
Benzinga Newsdesk

PRO
BTIG Reiterates Buy on Perspective Therapeutics, Maintains $14 Price Target

BTIG analyst Jeet Mukherjee reiterates Perspective Therapeutics (AMEX:CATX) with a Buy and maintains $14 price target.
Benzinga Newsdesk

PRO
Wedbush Reiterates Outperform on Perspective Therapeutics, Maintains $11 Price Target

Wedbush analyst David Nierengarten reiterates Perspective Therapeutics (AMEX:CATX) with a Outperform and maintains $11 price target.
Benzinga Newsdesk

Datos y APIs: APIs de Benzinga · API de noticias de acciones · API de calificaciones de analistas · API de logotipos de empresas

Datos de mercado proporcionados por APIs de Benzinga

Benzinga

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL

© 2026 Benzinga | All Rights Reserved